CBD
CBD (cannabidiol) is a non-intoxicating cannabis compound widely sold in oils, edibles, and topicals, with one FDA-approved prescription form (Epidiolex) for certain epilepsies. Hemp-derived CBD has been federally legal since the 2018 Farm Bill, but a 2025 law redefining hemp by total THC takes effect November 12, 2026 and may sweep in some CBD products.
Overview
CBD (cannabidiol) is one of the main compounds in cannabis, but unlike THC it does not produce a high. It is marketed widely as oils, gummies, capsules, and topical products for anxiety, pain, and sleep, though most such uses are not FDA-approved. One purified prescription form, Epidiolex, is FDA-approved to treat certain rare seizure disorders, which is the strongest evidence base for any CBD use.
Source: FDA; MedlinePlus; peer-reviewed literature (NIH/PMC)
Chemistry & mechanism of action
CBD's mechanism is complex and not fully understood. Unlike THC, it does not strongly activate the CB1 cannabinoid receptor, which is why it is non-intoxicating. Instead it interacts with a range of targets — including serotonin 5-HT1A receptors and the endocannabinoid system indirectly — and influences several drug-metabolizing liver enzymes, which is the basis of many of its drug interactions.
Source: peer-reviewed literature (NIH/PMC); FDA
Effects
CBD is generally reported to produce mild calming or anti-anxiety effects without intoxication. Common side effects, most clearly documented at the higher doses used medically, include drowsiness, diarrhea, changes in appetite, and fatigue. Effects from consumer products are inconsistent because potency and actual CBD content vary widely and are often mislabeled.
Source: FDA; peer-reviewed literature (NIH/PMC)
Risks & harms
CBD is not intoxicating and has a relatively favorable safety profile, but it is not risk-free. At higher doses it can cause liver enzyme elevations signaling potential liver injury, a risk flagged in the Epidiolex labeling. Its most important hazard is drug interactions: CBD inhibits liver enzymes that metabolize many medications, and can raise blood levels of drugs including certain blood thinners and anti-seizure medicines, potentially to dangerous levels — anyone on regular medication should treat this as a real interaction risk. The consumer market is poorly regulated: products are frequently mislabeled, containing more, less, or different cannabinoids than stated, and some have been found to contain THC (enough to cause intoxication or a positive drug test) or contaminants such as heavy metals or pesticides. Products are not a substitute for evidence-based medical treatment. Anyone with signs of liver problems (yellowing skin or eyes, severe abdominal pain) or a serious medication interaction should seek medical care; Poison Control at 1-800-222-1222 can advise on exposures. This page has not yet been medically reviewed.
Source: FDA; peer-reviewed literature (NIH/PMC); MedlinePlus
Legal status (US)
In the United States, hemp-derived CBD (from cannabis with no more than 0.3% delta-9 THC) has been federally legal since the 2018 Farm Bill removed hemp from the Controlled Substances Act, while CBD derived from marijuana remains federally controlled. The one FDA-approved CBD drug, Epidiolex, is not a controlled substance. Two changes matter: the FDA has stated CBD cannot lawfully be added to food or sold as a dietary supplement, and a 2025 federal law (effective November 12, 2026) redefines hemp using 'total THC' and excludes products over 0.4 mg total THC per container — which may pull some full-spectrum CBD products out of the legal hemp category. State laws also vary. This is a changing area; verify current federal and state law before relying on any status. This page has not yet been medically reviewed.
Source: FDA; DEA; US federal law (2018 Farm Bill; P.L. 119-37, eff. 2026-11-12); congress.gov
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling — penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authorityand your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulatein the destination immediately — notthe destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass — most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating — move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst — but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing — long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
With cannabis, anxiety or a racing heart usually pass with time. Sit somewhere calm, sip water, and rest — strong edibles in particular can take hours to ease.
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft — not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown — pending review”Identity
- PubChem CID
- 644019PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diolPubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C21H30O2PubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- CCCCCC1=CC(=C(C(=C1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)OPubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- QHMBSVQNZZTUGM-ZWKOTPCHSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- cannabidiol, (-)-Cannabidiol, (-)-trans-Cannabidiol, Epidiolex, delta1(2)-trans-Cannabidiol, CARDIOLRX, cannabidiolum, NanoCDB, Melody Cloverstrip, CBD OilPubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- HUMAN OTC DRUGopenFDA drug label ↗ · retrieved 2026-06-18
- Route
- TOPICALopenFDA drug label ↗ · retrieved 2026-06-18
- Shape
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Color
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Imprint
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Score
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- Unknown — pending review
Dosage
Pending medical reviewer
